In August the company was accepted into the AMPlify program (an accelerated market entry
platform), which is organized in collaboration with Mayo Clinic (USA) and Business Finland.
The program supports the commercialization projects of the company’s
ovarian cancer test currently under development.

Our ovarian cancer test is part of a broader cancer test portfolio based on
glycovariant determination technology currently in the research phase. The determination
leverages the company’s long-standing core expertise in immunoassay and instrument
technologies.